You're right, but because nuance isn't allowed on HN, you'll be down voted.
Primarily the focus has shifted to faster approvals with evidence for new methods and drugs coming down to one high quality trial, and removed stipulations for randomized control trials for ultra rare diseases.
> You're right, but because nuance isn't allowed on HN, you'll be down voted.
Nuance is fine. There's not much nuance in the parent post.
> the focus has shifted to faster approvals with evidence for new methods and drugs coming down to one high quality trial, and removed stipulations for randomized control trials for ultra rare diseases
Could you share how RFK's policies helped bring this to market faster? (Not challenging you, by the way. Just need help connecting the dots.)